Drug Profile
Research programme: companion diagnostic tests - PHIGENIX
Latest Information Update: 23 Jun 2021
Price :
$50
*
At a glance
- Originator PHIGENIX
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Prostate cancer
Most Recent Events
- 21 Jun 2021 Research programme: companion diagnostic tests - PHIGENIX is available for licensing as of 21 Jun 2021. https://www.phigenix.com/breast-cancer
- 15 Jun 2021 PHIGENIX has patent protection for the use and administration of certain PAX2 inhibitors for treating drug-resistant breast cancer in the US
- 28 Aug 2020 No recent reports of development identified for research development in Breast-cancer(Diagnosis) in USA